Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks
Executive Summary
‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.
You may also be interested in...
Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
Political Trials On All Sides: Lilly CEO Laments Loss Of ‘Chamber of Commerce Republicans’
David Ricks says the challenging political environment is empowering regulators. The Lilly leader also talked Twitter and drug prices, in a STAT Summit interview.
Cancer Drugs And Medicare: Range Of Impacts Expected From IRA Price Reforms
Alkermes discusses oncology drug spin-off, Lilly discloses decision to halt development of a small molecule drug, and AbbVie comments on pending Medicare price negotiation for Imbruvica.